![](/img/cover-not-exists.png)
BCR–ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response
Simara, Pavel, Peterkova, Martina, Stejskal, Stanislav, Potesilova, Michaela, Koutna, Irena, Racil, Zdenek, Razga, Filip, Jurcek, Tomas, Dvorakova, Dana, Mayer, JiriVolume:
53
Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.3109/10428194.2012.656104
Date:
August, 2012
File:
PDF, 191 KB
english, 2012